Urease-powered nanobots for radionuclide bladder cancer therapy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Urease-powered nanobots for radionuclide bladder cancer therapy. / Simó, Cristina; Serra-Casablancas, Meritxell; Hortelao, Ana C.; Di Carlo, Valerio; Guallar-Garrido, Sandra; Plaza-García, Sandra; Rabanal, Rosa Maria; Ramos-Cabrer, Pedro; Yagüe, Balbino; Aguado, Laura; Bardia, Lídia; Tosi, Sébastien; Gómez-Vallejo, Vanessa; Martín, Abraham; Patiño, Tania; Julián, Esther; Colombelli, Julien; Llop, Jordi; Sánchez, Samuel.
In: Nature Nanotechnology, Vol. 19, 2024, p. 554–564.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Urease-powered nanobots for radionuclide bladder cancer therapy
AU - Simó, Cristina
AU - Serra-Casablancas, Meritxell
AU - Hortelao, Ana C.
AU - Di Carlo, Valerio
AU - Guallar-Garrido, Sandra
AU - Plaza-García, Sandra
AU - Rabanal, Rosa Maria
AU - Ramos-Cabrer, Pedro
AU - Yagüe, Balbino
AU - Aguado, Laura
AU - Bardia, Lídia
AU - Tosi, Sébastien
AU - Gómez-Vallejo, Vanessa
AU - Martín, Abraham
AU - Patiño, Tania
AU - Julián, Esther
AU - Colombelli, Julien
AU - Llop, Jordi
AU - Sánchez, Samuel
N1 - Publisher Copyright: © 2024, The Author(s).
PY - 2024
Y1 - 2024
N2 - Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy.
AB - Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy.
U2 - 10.1038/s41565-023-01577-y
DO - 10.1038/s41565-023-01577-y
M3 - Journal article
C2 - 38225356
AN - SCOPUS:85182459825
VL - 19
SP - 554
EP - 564
JO - Nature Nanotechnology
JF - Nature Nanotechnology
SN - 1748-3387
ER -
ID: 380695287